Thalia Therapeutics (LSE:THAT) is strengthening its position in the RNA therapeutics sector through the proposed acquisition of Sanmirna Therapeutics and an oversubscribed £2.75 million fundraising, supporting its transition into a clinical-stage biotechnology company.
The proposed transaction will add miRisten, a Phase 1 microRNA therapy for Acute Myeloid Leukaemia (AML), to Thalia’s development portfolio. Combined with the company’s proprietary Nuvec delivery platform and its cardiovascular small interfering RNA (siRNA) programme, the acquisition is expected to create a broader pipeline focused on oncology and cardiovascular disease.
Following the successful fundraising, Thalia plans to use the proceeds to support key development milestones. Its immediate priorities include completing the acquisition of Sanmirna, advancing the ongoing Phase 1 trial of miRisten, with topline data expected during the first half of 2027, and progressing its cardiovascular candidate towards investigational new drug (IND)-enabling studies.
Management believes these milestones will enhance the company’s long-term growth prospects and strengthen its position within the rapidly expanding global RNA therapeutics market, where it aims to build a diversified clinical-stage pipeline addressing areas of significant unmet medical need.
Despite having no debt, Thalia’s financial outlook continues to reflect the characteristics of a development-stage biotechnology company, including ongoing losses and continued cash burn. However, recent share price performance has remained above key technical moving averages, providing some positive momentum, while valuation metrics remain limited by the company’s lack of profitability and the absence of a dividend.
More about Thalia Therapeutics plc
Thalia Therapeutics plc is an AIM-listed biotechnology company developing RNA-based medicines and drug delivery technologies targeting oncology and cardiovascular diseases. Its portfolio includes the proprietary Nuvec delivery platform, a cardiovascular siRNA programme and, subject to completion of the proposed acquisition, the Phase 1 microRNA therapy miRisten for the treatment of Acute Myeloid Leukaemia.
The company’s strategy is focused on building a diversified clinical-stage RNA therapeutics pipeline that combines innovative delivery technology with high-value therapeutic programmes. By targeting large global markets with significant unmet medical needs, Thalia aims to establish itself as a leading developer of next-generation RNA-based treatments.
‘ Este Articulo puede contener información publicada por terceros, algunos detalles de este articulo fueron extraídos de la siguiente fuente: uk.finance.yahoo.com ’
